Construction and biological activity of a recombinant bispecific single- chain antibody designed for therapy of minimal residual colorectal cancer

Cancer Immunology Immunotherapy

Volumn 45, Issue 3-4, 1997, Pages 193-197

  Kufer, P ^a   Mack, M ^a   Gruber, R ^a   Lutterbuse R ^a   Zettl, F ^a   Riethmuller G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biological properties; Bispecific single chain antibody; Colorectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHO CELL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG DESIGN; DRUG SYNTHESIS; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; HUMAN CELL; METASTASIS; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHO CELLS; COLORECTAL NEOPLASMS; CRICETINAE; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASM, RESIDUAL; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 0030772184     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050431     Document Type: Article

References (11)

1. Göttlinger HG, Funke I, Johnson JP, Gockel FG, Riethmüller G (1986) The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 38: 47
2. Kroesen BJ, Buter J, Sleijfer DT, Janssen RA, Graaf WT van der. The TH, Leij L de, Mulder NH (1994) Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous inerleukin 2. Br J Cancer 70: 652
3. Mack M, Riethmüller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 92: 7021
4. Mack M, Gruber R, Schmidt S, Riethmüller G, Kufer P (1997) Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3. J Immunol 158: 3965
5. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM (1985) Specific targeting of cytotoxic T-cells by anti-T3 linked to antitarget cell antibody. Nature 316: 354
6. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichelmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, The German Cancer Aid 17-1A Study Group (1992) Randomized trial of monoclonal antibody for adjuvant therapy of resected colorectal carcinoma. Lancet 343: 1177
7. Riethmüller G, Holz E, Schlimok G. Schmiegel W, Raab R, Höffken K, Gruber R, Pichelmaier H, Hirche H, Pichlmayr R, The German Cancer Aid 17-1A Study Group (1996) Monoclonal antibody (mAb) adjuvant therapy of Dukes C colorectal carcinoma: 7-year update of a prospective randomized trial. Proc Am Soc Clin Oncol Annu Meet 15: 444
8. Shen J, Atkinson B, Koprowski H, Sears HF (1984) Binding of human immunoglobulin to human tissues after immunotherapy with anticolorectal carcinoma monoclonal antibody. Int J Cancer 33: 465
9. Staerz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T-cells. Nature 314: 628
10. Tibben JG, Boerman OC, Claessens RA, Corstens RH, van Deuren M, Mulder PH de, van der Meer JW, Keijser KG, Massuger LF (1992) Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab′)2. J Natl Cancer Inst 85: 1003
11. Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402